Please login to the form below

Not currently logged in
Email:
Password:

Paul Navarre moves from Allergan to Ferring Pharmaceuticals

Takes up CEO role at its Ferring Holding subsidiary

Paul NavarreFerring Pharmaceuticals has appointed Paul Navarre as CEO of Ferring Holding Inc - a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharma company - in a role that will see him assume responsibility for all of the group’s activities including commercial operations, clinical development and manufacturing.

Navarre has more than 25 years’ experience in the pharmaceuticals and consumer good industries and joins from Allergan, where he was president of Allergan International and managed a $3bn speciality care business covering dermatology, ophthalmology, urology and neurosciences.

Before joining Allergan, Navarre spent 15 years at Procter & Gamble holding positions in France, USA, Switzerland, Italy and the UK.

He said: “Ferring is a fast growing pharmaceutical company with a unique culture centred on people and patients.

“I am very excited to lead this organisation into the next phase of its development.”

As CEO, Navarre will report to the board of directors chaired by Michel Pettigrew, president of the executive board and chief operating officer of Ferring Group.

Pettigrew said: “Paul’s extensive pharmaceutical speciality care experience and proven international leadership skills will help him take our successful US operations to the next level, pursuing our rapid extension.”

Navarre succeeds Aaron Graff who has been appointed to a global role as executive vice president, chief commercial officer and member of the Ferring Group executive board.

6th June 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics